Consistent with our findings, the results from the ORAL Surveillance trial in patients with cardiovascular risk factors suggested an increased risk of serious infections in elderly patients (aged 65 years or older) treated with TOF 10mg twice daily compared to TNF inhibitors19. This evidence concerns the gene TNF and infection.